Vector Laboratories Acquires Quanta BioDesign

Vector Laboratories announced the acquisition of Quanta BioDesign on July 17, 2023, which further expands the former’s portfolio of bioconjugation linkers and dyes, as well as its manufacturing sector, according to the press release.

“This acquisition is valuable because it supports Vector Laboratories’ long-term strategic vision of accelerating the pace of scientific discovery for life science companies and transformational treatments and approaches for biopharma companies,” said Lisa V. Sellers, PhD, CEO of Vector Laboratories, in a press release. “It also builds on our recent acquisition of Click Chemistry Tools and Fluoroprobes and goes beyond standard linker capabilities to serve broader industrial segments, expanding what’s possible for customers in manufacturing components for their end products. We can now offer a breadth of options to provide the best solution for our customers’ challenges.”

Quanta BioDesign is responsible for patented and innovative cross-linking and labeling chemistries that are enabled by dPEG technology, according to the press release. Further, the company focuses on drug discovery and diagnostic development programs.

“I am pleased that Vector Laboratories, with its eye toward innovation and a proven record in bringing high-quality products to market, recognized how our offerings will complement and help grow its portfolio. I’m confident they will continue the work I started in specifically designed monodispersed (dPEG) reagents for applications in the therapeutic and diagnostic markets,” said founder Paul D. Davis, PhD, in a press release. “I am eager to focus on being a scientific ambassador working both with the Vector Laboratories team and our customers to further drug discovery and diagnostic development.”

Source: Vector Laboratories